The exosite drug developer has launched publicly to advance research from Harvard University and Salk Institute for Biological Studies.
Exo Therapeutics, US-based small molecule drug developer based on research at Harvard University and Salk Institute for Biological Studies, emerged from stealth yesterday having closed a $25m series A round featuring pharmaceutical firm Novartis, which invested through its Novartis Venture Fund.
The round included 6 Dimensions Capital, the investment firm formed by the merger of pharmaceutical company WuXi AppTec’s WuXi Healthcare Ventures unit and VC firm Frontline BioVentures, in addition to CRV and Newpath Partners.
Exo is working…
